- Home
- WRB vs RPRX Comparison
WRB vs RPRX Comparison
Compare WRB & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRB | RPRX |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | 8804 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 22.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WRB | RPRX |
|---|---|---|
| Price | $70.25 | $54.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $68.86 | $51.40 |
| AVG Volume (30 Days) | 2.0M | ★ 3.7M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.78% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $5.18 | $38.63 |
| Revenue Next Year | $4.95 | $4.73 |
| P/E Ratio | ★ $15.91 | $82.61 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $62.87 | $34.63 |
| 52 Week High | $78.96 | $56.50 |
Technical Indicators
Market Signals| Indicator | WRB | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 55.56 |
| Support Level | $65.14 | $35.33 |
| Resistance Level | $71.18 | $56.50 |
| Average True Range (ATR) | 1.36 | 1.38 |
| MACD | 0.25 | -0.21 |
| Stochastic Oscillator | 96.21 | 68.79 |
Price Performance
Historical ComparisonAbout WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.